Lipid Nanoparticle-Mediated Lymphatic Delivery of Immunostimulatory Nucleic Acids

Lymphatic delivery of a vaccine can be achieved using a dendritic cell (DC)-targeted delivery system that can cause DC to migrate to lymph nodes upon activation by an adjuvant. Here, we designed a mannose-modified cationic lipid nanoparticle (M-NP) to deliver the nucleic acid adjuvant, polyinosinic:...

Full description

Saved in:
Bibliographic Details
Published in:Pharmaceutics 2021-04, Vol.13 (4), p.490
Main Authors: Kim, Dongyoon, Wu, Yina, Shim, Gayong, Oh, Yu-Kyoung
Format: Article
Language:English
Subjects:
Acids
Antigens
Bone marrow
Coronaviruses
dendritic cell-targeted delivery
Dendritic cells
Flow cytometry
Laboratory animals
lipid nanoparticle
Lipids
lymphatic delivery
Lymphatic system
Microscopy
Morphology
Nanoparticles
nucleic acid adjuvant
Particle size
Pathogens
Vaccines
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Lymphatic delivery of a vaccine can be achieved using a dendritic cell (DC)-targeted delivery system that can cause DC to migrate to lymph nodes upon activation by an adjuvant. Here, we designed a mannose-modified cationic lipid nanoparticle (M-NP) to deliver the nucleic acid adjuvant, polyinosinic:polycytidylic acid (PIC). PIC-loaded M-NP (PIC/M-NP) showed stable lipoplexes regardless of the ligand ratio and negligible cytotoxicity in bone marrow-derived DC. DC uptake of PIC/M-NP was demonstrated, and an increased mannose ligand ratio improved DC uptake efficiency. PIC/M-NP significantly promoted the maturation of bone marrow-derived DC, and local injection of PIC/M-NP to mice facilitated lymphatic delivery and activation (upon NP uptake) of DC. Our results support the potential of PIC/M-NP in delivering a nucleic acid adjuvant for the vaccination of antigens.
ISSN:1999-4923
1999-4923
DOI:10.3390/pharmaceutics13040490